Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 3/20 | 0.44 |
| ▸ | LDLR | P01130 | 1/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 11/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.41 |
| ▸ | WNT1 | P04628 | 3/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | CLK3 | P49761 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19064527 | 0.85 | HPGDS (0.50) | HPGDSIDO1LDLRPCSK9GSK3B | |
| SCHEMBL22845306 | 0.77 | IDO1 (0.47) | HPGDSIDO1LDLRPCSK9GSK3B | |
| SCHEMBL4022684 | 0.76 | HPGDS (0.54) | HPGDSIDO1LDLRPCSK9GSK3B | |
| SCHEMBL20255466 | 0.76 | HPGDS (0.54) | HPGDSIDO1LDLRPCSK9GSK3B | |
| SCHEMBL6408857 | 0.76 | IDO1 (0.54) | HPGDSIDO1LDLRPCSK9GSK3B | |
| SCHEMBL14327688 | 0.75 | KIF11 (0.38) | CLK2 | |
| SCHEMBL1502339 | 0.74 | IDO1 (0.51) | HPGDSIDO1LDLRPCSK9GSK3B | |
| SCHEMBL13728605 | 0.73 | HPGDS (0.51) | HPGDSIDO1LDLRPCSK9GSK3B | |
| Ammonia Solution, Strong SCHEMBL28862527 | 0.73 | IDO1 (0.50) | HPGDSIDO1LDLRPCSK9GSK3B | |
| SCHEMBL10154082 | 0.72 | IDO1 (0.46) | HPGDSIDO1LDLRPCSK9GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | HPGDS 1953/4885IDO1 2481/4885LDLR 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.